Spyre Therapeutics, Inc. (SYRE) shares gained 4.16 percent, rising $2.88 to $72.04 on Wednesday after the clinical-stage biotechnology company announced the completion of enrollment across all sub-studies in the SKYWAY Phase 2 basket trial evaluating SPY072, its investigational anti-TL1A therapy, in rheumatic diseases.
The stock is currently trading at $72.04 on the Nasdaq, compared with its previous close of $69.16. During the session, it opened at $70.05 and traded between $69.82 and $76.11. Trading volume reached 438,603 shares.
The company said enrollment was completed in less than nine months, highlighting strong interest in the potential treatment among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Management noted that the milestone keeps the company on track to deliver five of its six planned Phase 2 data readouts in 2026.
Spyre Therapeutics shares have traded between $13.93 and $78.80 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.